1.Carcinosarcoma of the Urinary Bladder with Rapid Growth: A Case Report
Taku Naiki ; Noriyasu Kawai ; Daisuke Nagata ; Yutaka Andoh ; Hideyuki Kamisawa ; Toshiki Katoh ; Hidetoshi Akita ; Takehiko Okamura
Journal of Rural Medicine 2008;4(1):27-31
Carcinosarcoma of the bladder is a rare malignancy characterized by an intimate admixture of malignant epithelial elements (carcinoma) and malignant soft tissue elements (sarcoma). Patients with carcinosarcoma usually present with high-stage malignancy. Cystectomy or transurethral resection of the bladder tumor (TUR-Bt) is the preferred treatment, often followed by radiation therapy, but the prognosis is very poor1-7). To our knowledge, almost 80 cases have been reported in Japan, usually as case reports or small series6, 7). In almost all cases, the chief complaint was gross hematuria. We herein report a case of carcinosarcoma of the urinary bladder in a patient whose chief complaint was abdominal pain. His pain worsened, and the occurrence of hydronephrosis indicated that extremely rapid tumor growth may have occurred. No evidence of recurrence was noted 30 months after the performance of cystectomy.
Carcinosarcoma
;
Bladder
;
Malignant Neoplasms
;
Rapid
;
Case Report
2.Recurrence of Seminoma in the Scrotum after Orchidectomy
Yasuhiko Hirose ; Hidetoshi Akita ; Toshiki Kato ; Hideyuki Kamisawa ; Yoshinobu Moritoki ; Takehiko Okamura
Journal of Rural Medicine 2007;3(2):34-36
Recurrence of seminoma in the scrotum after inguinal orchidectomy is extremely rare. Herein, we report the second case in the literature of recurrence of seminoma in the scrotum following inguinal orchidectomy for stage I seminoma.
Seminoma
;
Recurrence
;
Disease of scrotum
;
Benign neoplasm of scrotum
;
Orchiectomy
3.Severe Hemolytic Uremic Syndrome Associated with Cisplatin-based Chemotherapy for Advanced Bladder Cancer
Taku Naiki ; Satoshi Ishikawa ; Hideyuki Kamisawa ; Toshiki Kato ; Hidetoshi Akita ; Takehiko Okamura
Journal of Rural Medicine 2007;3(2):37-40
Hemolytic uremic syndrome (HUS) is a heterogeneous disorder characterized by hemolytic anemia, thrombocytopenia and renal failure that occurs predominantly in infants and young children. However, HUS in adults has also been described as a complication of various chemotherapy regimens with a relatively poor prognosis. Since cisplatin is now widely used for treatment of solid cancers, it is necessary to take into account the possibility of cisplatin-induced hemolytic uremic syndrome as a rare but potentially fatal side- effect. Herein, we describe our experience with a 67-year old woman being treated for a urothelial carcinoma of the bladder who suffered chemotherapy-induced HUS after a cisplatin-based regimen. Plasmapheresis was carried out five times; however, her serum platelets remained depressed, and she subsequently died. We conclude that there is a high risk potential for HUS in patients undergoing intensive chemotherapy for advanced-stage bladder cancer.
Hemolytic-Uremic Syndrome
;
Chemotherapy-Oncologic Procedure
;
Cisplatin
;
Cancer of Bladder
;
regimen
4.Early-Stage Clinical Experiences of Holmium Laser Enucleation of the Prostate (HoLEP)
Shuzo Hamamoto ; Takehiko Okamura ; Hideyuki Kamisawa ; Kentaro Mizuno ; Makoto Katou ; Kenjiro Kohri
Journal of Rural Medicine 2006;2(2):93-97
Objective: Recently, holmium laser enucleation of the prostate (HoLEP) has been established as one method of endoscopic surgery for the treatment of benign prostate hyperplasia (BPH). The purpose of our study was to assess initial clinical experiences with HoLEP at our hospital.;Patients and Methods: A retrospective analysis was conducted of 28 patients with obstructive symptoms due to BPH who underwent HoLEP during the 13 months between February 2004 and March 2005.;Results: The mean age of the patients was 67.4 years (range 59 to 78 years). The mean enucleation tissue weight was 24.3 g (range 2 to 95 g), and the average operation time was 94.1 minutes (range 40 to 268 minutes). The mean duration of postoperative catheterization was 3.4 days (range 1 to 6 days). The mean urine flow rate improved, and each patient's satisfaction for voiding, measured on a 5-point scale, was good. There were no major complications during the operations except one case, which was completed with TUR-P because of uncontrollable bleeding. No patients required transfusions. Long-term complications included five cases of stress incontinence (19%), four of urethral stricture (14%), and three temporary retention, two of which required re-catheterization (10%).;Conclusion: HoLEP can be performed without major intraoperative complications. It is an effective treatment for obstructive symptoms due to BPH. However, there are many postoperative problems that must be resolved, including stress incontinence and urethral stricture because of our lack of experience, with HoLEP.
Enucleation
;
Prostatic Hypertrophy, Benign
;
Complications Specific to Antepartum or Postpartum
;
Lasers
;
Holmium
5.Seminomatous Extragonadal Germ Cell Tumor with Complete Obstruction of the Superior Vena Cava Responding to Intensive Chemotherapy
Yoshinobu Moritoki ; Toshiki Kato ; Hidenori Nishio ; Hideyuki Kamisawa ; Yasuhiko Hirose ; Ryosuke Ando ; Hidetoshi Akita ; Takehiko Okamura ;
Journal of Rural Medicine 2011;6(1):32-34
A 20-year-old man was admitted to our hospital with persistent cough and dyspnea. He had bilateral distention of the jugular veins, and swollen lymph nodes were palpable in the right subclavicular region. Plain X-ray and computed tomography (CT) of the chest showed a solid soft tissue mass in the upper mediastinum, with leftward displacement of the trachea and complete obstruction of the superior vena cava. Mediastinal radiotherapy (1.8 Gy/day) and methylprednisolone (100 mg/day) were started immediately. Biopsy of the right subclavicular lymph nodes revealed metastatic seminoma. The patient was referred for chemotherapy, which was performed with a combination of cisplatin, bleomycin and etoposide (BEP). A partial response was observed after completion of 3 cycles of chemotherapy, but there was no further tumor shrinkage after additional salvage chemotherapy. The patient is being followed up on an outpatient basis and has been free of recurrence for 32 months after intensive treatment.